See the DrugPatentWatch profile for cosentyx

When using Cosentyx (secukinumab), a medication used to treat several conditions including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis, certain precautions should be taken when administering live vaccines.

Cosentyx, like other biologic agents, may affect your immune system's response to live vaccines [1]. Therefore, it is recommended to avoid live vaccines during Cosentyx treatment and for some time after discontinuing the medication [2].

The Centers for Disease Control and Prevention (CDC) recommends that live vaccines be given at least 4 weeks before starting Cosentyx, if possible [3]. However, the optimal timing may vary depending on the specific vaccine and individual patient factors. It is essential to consult with a healthcare provider to determine the best course of action.

It is also important to note that individuals receiving Cosentyx should not receive the BCG (Bacillus Calmette-Guérin) vaccine, which is used to prevent tuberculosis (TB), due to the risk of severe infection [4].

In summary, when using Cosentyx, the following precautions should be taken regarding live vaccines:

1. Avoid live vaccines during Cosentyx treatment and for some time after discontinuing the medication.
2. Consult with a healthcare provider to determine the best timing for live vaccines.
3. Do not receive the BCG vaccine while on Cosentyx.

Sources:
[1] Novartis. (2021). Cosentyx (secukinumab) [Prescribing Information]. Retrieved from <https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/cosentyx.pdf>
[2] American Academy of Dermatology. (2021). Biologic Therapies for Psoriasis. Retrieved from <https://www.aad.org/public/diseases/psoriasis/treatment/biologics>
[3] Centers for Disease Control and Prevention. (2021). Vaccination of Persons with Moderately or Severely Compromised Immune Systems. Retrieved from <https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/clinical-considerations.html#live-vaccines>
[4] World Health Organization. (2018). Position Paper: Bacillus Calmette-Guérin (BCG) Vaccine. Retrieved from <https://www.who.int/wer/2018/wer9322.pdf>

Additional source:
DrugPatentWatch.com. (n.d.). Secukinumab (Cosentyx). Retrieved from <https://www.drugpatentwatch.com/drugs/secukinumab>